Journal of Diagnostics Concepts & Practice >

2020 , Vol. 19 >Issue 02: 177 - 181

DOI: https://doi.org/10.16150/j.1671-2870.2020.02.015

Original articles

Application of plastic-embedded bone marrow biopsy in diagnosing myelodysplastic syndrome with thrombocytopenia

Expand
  • 1. Division of Hematology, Shidong Hospital, Shanghai 200438, China
    2. Department of Oncology, Shanghai International Medical Center, Shanghai 201318, China

Received date: 2020-01-09

  Online published: 2020-04-25

Fold

Abstract

Objective: To explorethe value of megakaryocyte immunolabeling performed on bone marrow biopsy section embedded in glycol-methacrylate (GMA) plastic in the diagnosis of myelodysplastic syndrome (MDS) with thrombocytopenia. Methods: Bone marrow biopsy samples acquired from 47 patients with thrombocytopenia were processed with glycol-methacrylate (GMA) embedding technique, and megakaryocyte immunolabeling were performed. Results: Bone marrow biopsy plastic embedded technology improved themorphologic diagnosis of MDS, and megakaryocyte immunolabeling enabled identification of the small or micor sized megakaryocyte. Out of the cases examined, 8 were diagnosed as myelodysplastic syndrome (MDS), including 3 cases of myelodysplastic syndrome-single lineage dysplasia (MDS-SLD), 1 case of 5q- syndrome and 4 cases of myelodysplastic syndrome-multilineage dysplasia (MDS-MLD). All of the 8 cases were positive for megakaryocyte markers, and 6 cases of them showed clear abnormal localization of immature precursor (ALIP) in the section, and 3 cases had chromosomal abnormalities detected. Conclusion: Combination of GMA plastic embedded technology and megakaryocyte immunolabeling facilitate the diagnosis of MDS with thrombocytopenia.

Key words： Bone marrow biopsy; Plastic embedding; Myelodysplastic syndrome; Thrombocytopenia

Cite this article

YE Chenglin, YAO Yonghua, CHEN Zhen, JIA Lin . Application of plastic-embedded bone marrow biopsy in diagnosing myelodysplastic syndrome with thrombocytopenia[J]. Journal of Diagnostics Concepts & Practice, 2020 , 19(02) : 177 -181 . DOI: 10.16150/j.1671-2870.2020.02.015

References

[1] 浦杰, 石军, 陈真, 等. 骨髓活检标本乙二醇-甲基丙烯酸酯塑胶包埋切片免疫组织化学检测的研究[J]. 诊断学理论与实践, 2016, 15(3):312-316.
[2] 浦权, 姚永华. 实用血液病骨髓病理学彩色图谱[M]. 北京: 科学出版社, 2017:7-9.
[3] 浦权. 解读骨髓增生异常综合征WHO(2016)分型的修订[J]. 新医学, 2017, 48(3):137-142.
[4] 文瑞婷, 杨志刚, 龙杰, 等. 血小板生成素对血小板减少性疾病鉴别诊断及疗效判断的应用价值[J]. 中国实验诊断学, 2016, 20(6):955-958.
[5] Cybulska A, Meintker L, Ringwald J, et al. Measurements of immature platelets with haematology analysers are of limited value to separate immune thrombocytopenia from bone marrow failure[J]. Br J Haematol, 2017, 177(4):612-619.
[6] 刘柳, 崔雯, 张宏丽, 等. 骨髓增生异常综合征患者有核红细胞糖原染色的意义[J]. 中华血液学杂志, 2011, 32(4):259-264.
[7] 张京, 杨柯, 白海, 等. 血液病骨髓涂片与骨髓病理活检诊断对比分析[J]. 检验医学与临床, 2017, 14(3):408-410.
[8] 杨娣娣, 韩秀蕊, 张丽洁, 等. 3374例血液病患者骨髓细胞形态及活检同步检测的比较分析[J]. 中国实验诊断学, 2016, 20(6):952-954.
[9] 浦杰, 陈真, 石军, 等. 骨髓活检组织病理在骨髓增生异常综合征诊断中的价值[J]. 重庆医学, 2014, 43(3):257-259.
[10] Vrbensky JR, Nazy I, Toltl LJ, et al. Megakaryocyte apoptosis in immune thrombocytopenia[J]. Platelets, 2018, 29(7):729-732.
[11] 董海波, 谢品浩, 袁翠英, 等. 病态造血在骨髓增生异常综合征诊断中的意义[J]. 检验医学与临床, 2016, 13(5):685-688.
[12] Xiong B, Nie Y, Tang Z, et al. Prognostic evaluation of ALIP and CD34 immunostaining in IPSS-R subgroups of myelodysplastic syndromes[J]. Pathology, 2017, 49(5):526-533.
[13] Mortensen TB, Frederiksen H, Marcher CW, et al. Refractory primary immune thrombocytopenia with subsequent del(5q) MDS: complete remission of both after lenalidomide[J]. BMJ Case Rep, 2017,2017.
[14] Ghanima W, Boiocchi L, Lee CS, et al. Immune thrombocytopenia is associated with persistently deranged fibrosis-related seromarker profiles but low bone marrow fibrosis grades: A 2-year observational study on thrombopoietin receptor agonist treatment[J]. Platelets, 2019, 30(2):222-228.
Options
Outlines

/

〈 〉